Posted by Michael Wonder on 21 Dec 2023
4DMT receives FDA regenerative medicine advanced therapy designation for 4D-150 genetic medicine for intravitreal treatment of wet AMD, the first RMAT designation in wet AMD
21 December 2023 - Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration.
4D Molecular Therapeutics today announced that the US FDA has granted the RMAT designation for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet age-related macular degeneration.
